3 Results for "

EGFR/HER2-IN-4

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "EGFR/HER2-IN-4" in MCE Product Catalog:

Cat. No.: HY-147992
CAS No.: 1879071-89-2
Target:  

EGFR

Research Areas:  

Cancer

EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits EGFR with an IC50 value of 0.6 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10261B
CAS No.: 439081-18-2
Purity:  99.98%
Synonyms: (E/Z)-BIBW 2992
Research Areas:  

Others Cancer

(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
loading...
    loading...
Cat. No.: HY-10261BR
CAS No.: 439081-18-2
Synonyms: (E/Z)-BIBW 2992 (Standard)
(E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .
loading...
    loading...